Media coverage about Marinus Pharmaceuticals (NASDAQ:MRNS) has been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Marinus Pharmaceuticals earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.8262666513668 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news headlines that may have impacted Accern’s rankings:

Shares of Marinus Pharmaceuticals traded down $0.06, hitting $5.86, on Friday, MarketBeat.com reports. 340,686 shares of the company traded hands, compared to its average volume of 590,393. The stock has a market cap of $244.37 million, a P/E ratio of -7.33 and a beta of 2.67. Marinus Pharmaceuticals has a 12-month low of $2.34 and a 12-month high of $9.87.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.09). equities research analysts forecast that Marinus Pharmaceuticals will post -0.68 EPS for the current year.

Several analysts have issued reports on MRNS shares. BidaskClub cut shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 22nd. Cantor Fitzgerald set a $19.00 price objective on shares of Marinus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday. Mizuho restated a “buy” rating and set a $13.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, August 2nd. LADENBURG THALM/SH SH initiated coverage on shares of Marinus Pharmaceuticals in a research report on Wednesday, June 6th. They set a “buy” rating and a $20.00 price objective on the stock. Finally, ValuEngine upgraded shares of Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. Nine analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average target price of $18.43.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

Featured Story: Stock Symbol

Insider Buying and Selling by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.